Search
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnPrior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. … The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding
Tagatose
go.drugbank.com/drugs/DB04936InvestigationalIt is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener. … Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.
Morphine
go.drugbank.com/drugs/DB00295ApprovedInvestigational[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.
Synonyms: (5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diolCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAn anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. … In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce
Categories: Analgesics, Non-NarcoticVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Enoxacin
go.drugbank.com/drugs/DB00467ApprovedA broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
Dermatophagoides farinae
go.drugbank.com/drugs/DB10400ApprovedInvestigationalDermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for ...
Dermatophagoides pteronyssinus
go.drugbank.com/drugs/DB10401ApprovedInvestigationalDermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...